{
    "nctId": "NCT02544997",
    "briefTitle": "A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway",
    "officialTitle": "A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically confirmed metastatic breast cancer with measurable or evaluable disease\n2. age \u2265 20 years\n3. HER2 mutation or EGFR mutation/gene amplification confirmed by CancerSCAN or Activated AR pathway confirmed by RNA seq \\& nCounter assay, AR expression was confirmed by immunohistochemistry(IHC) or EGFR high expression (\u2265 IHC 2+ \\& lower ER / \u2265 IHC score + and HER2 2+ or SISH negative)\n4. ECOG performance status 0 - 2\n5. Two or more regimens for locally recurrent or metastatic breast cancer, including an anthracycline and a taxane\n6. Life expectancy \u2265 3 months\n7. Progression within 6 months or less of latest chemotherapy\n8. The patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. Prior radiotherapy must be completed 2 weeks before study entry.\n9. Adequate bone marrow function (\u2265 ANC 1,500/ul, \u2265 platelet 100,000/ul, \u2265 Hemoglobin 9.0 g/dl)\n10. Adequate renal function (serum creatinine \u2264 1.5 x upper normal limit or CCr \u2265 50 ml/min)\n11. Adequate liver function (serum bilirubin \u2264 1.5 x upper normal limit, AST/ALT \u2264 3 x upper normal limit)\n12. No prior history of pan-HER TKI including poziotinib for metastatic breast cancer\n13. Written informed consent\n\nExclusion Criteria:\n\n1. HER2-overexpressing breast cancer\n2. Serious uncontrolled intercurrent infections\n3. Serious intercurrent medical or psychiatric illness, including active cardiac disease\n4. Pregnancy or breast feeding\n5. Second primary malignancy(except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or resected thyroid papillary carcinoma or other malignancy treated at least 5 years previously with no evidence of recurrence)\n6. Documented leptomeningeal brain metastasis\n7. Known brain metastases unless treated and stable\n8. Peripheral neuropathy \u2265 grade 3\n9. Prior treatment with pan-HER TKI including poziotinib will not be allowed.\n10. Use of any investigational drug within 4 weeks of the study\n11. Treatment with chemotherapy or hormone therapy within 3 weeks of the study",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}